Drug profile · INN
itraconazole
ITRACAP
itraconazole (ITRACAP) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — itraconazole
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 2
- Programs
- 20
- Data quality
- 0.89
Quick answer
itraconazole (ITRACAP) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 51 inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is itraconazole?
itraconazole (ITRACAP) is a cytochrome p450 51 inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for itraconazole?
ITRACAP is a marketed brand name for itraconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of itraconazole?
itraconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.